SOUTH SAN FRANCISCO, CA, USA I May 6, 2025 I IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and ...

Company is advancing a new class of immunomodulators for autoimmune and inflammatory disorders with high unmet medical need- ...

New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism ...

INGELHEIM, Germany I May 6, 2025 I Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the ...

SAN DIEGO, CA, USA I May 5, 2025 I Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development ...

SUZHOU, China I May 5, 2025 I CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, ...

PLAINSBORO, NJ, USA I May 2, 2025 I Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application ...

SHANGHAI, China I April 30, 2025 I Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented 6 study results ...

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) ...

OBI is a clinical stage global oncology company that is headquartered in Taiwan and established in 2002. Its mission, together with its wholly owned subsidiary OBI Pharma USA, Inc., is to develop ...

CAMBRIDGE, MA, USA I April 30, 2025 I Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the first participant has been dosed in the pivotal Phase 3 LUCIDITY ...